Medicare de-fangs new drug pricing model

The Trump administration has finalized a Medicare payment model designed to reduce drug costs for medications administered in doctors’ offices by aligning them with prices paid in other developed nations. The move targets high-cost treatments, potentially saving billions by preventing overcharging in outpatient settings. Critics argue the approach could limit patient access to certain drugs, while supporters say it forces pharmaceutical companies to adopt fairer pricing. The policy marks a significant shift in how Medicare negotiates drug reimbursements outside hospitals.

Click in for more news from The Hill {beacon} Healthcare Healthcare   The Big Story Medicare de-fangs new drug pricing model The Trump administration rolled out the final version of a new Medicare payment model aimed at lowering the prices of drugs administered in doctors’ offices to match those paid in countries overseas. © Nam...